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Abstract: Neuraminidase inhibitors (NAIs) are vital in managing seasonal and pandemic 
influenza infections. NAI susceptibilities of virus isolates (n = 5540) collected during the 
2008–2009 influenza season were assessed in the chemiluminescent neuraminidase inhibition 
(NI) assay. Box-and-whisker plot analyses of log-transformed IC50s were performed for each 
virus type/subtype and NAI to identify outliers which were characterized based on a statistical 
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cutoff of IC50 >3 interquartile ranges (IQR) from the 75th percentile. Among 1533 seasonal 
H1N1 viruses tested, 1431 (93.3%) were outliers for oseltamivir; they all harbored the H275Y 
mutation in the neuraminidase (NA) and were reported as oseltamivir-resistant. Only 15 
(0.7%) of pandemic 2009 H1N1 viruses tested (n = 2259) were resistant to oseltamivir. All 
influenza A(H3N2) (n = 834) and B (n = 914) viruses were sensitive to oseltamivir, except for 
one A(H3N2) and one B virus, with D151V and D197E (D198E in N2 numbering) mutations 
in the NA, respectively. All viruses tested were sensitive to zanamivir, except for six seasonal 
A(H1N1) and several A(H3N2) outliers (n = 22) which exhibited cell culture induced 
mutations at residue D151 of the NA. A subset of viruses (n = 1058) tested for peramivir were 
sensitive to the drug, with exception of H275Y variants that exhibited reduced susceptibility to 
this NAI. This study summarizes baseline susceptibility patterns of seasonal and pandemic 
influenza viruses, and seeks to contribute towards criteria for defining NAI resistance. 
Keywords: Oseltamivir; zanamivir; peramivir; seasonal influenza A and B; pandemic H1N1 
 
1. Introduction 
Antiviral drugs play an essential role in the management of infections caused by seasonal and 
pandemic influenza viruses. Adamantanes (M2 ion channel blockers) and neuraminidase inhibitors (NAIs) 
are two classes of drugs licensed for prevention or treatment of influenza A virus infections [1], however, 
the effectiveness of adamantanes is compromised by resistance among seasonal influenza A(H3N2) and 
A(H1N1) viruses circulating in certain geographic areas [2,3]. 
Two FDA-approved NAIs, oseltamivir and zanamivir, are presently the only antiviral drugs that are 
effective for the treatment and chemoprophylaxis of seasonal as well as 2009 H1N1 pandemic influenza 
infections. An investigational NAI, peramivir, developed as an intravenous (IV) formulation, was recently 
prescribed in the United States under an emergency use authorization (EUA) for treatment of 2009 
pandemic influenza H1N1 infection in certain patients [4] and is now licensed in Japan [5]. Another 
neuraminidase inhibitor, R-125489, is being developed by Daiichi Sankyo and Biota as an inhaled 
prodrug, laninamivir (CS-8958). NAIs competitively bind to the highly conserved NA active site which 
comprises of catalytic and framework residues [6]. Mutations at this site arise from single amino acid 
changes [7] which confer resistance to NAIs in a drug- and virus type/NA subtype-specific manner. 
Prior to 2007, resistance to NAIs among circulating influenza viruses was low (<1% worldwide)  
[8–10]. However, the 2007–2008 influenza season was marked by an emergence of oseltamivir-resistant 
seasonal influenza A(H1N1) viruses with the H275Y (H274Y in N2 numbering) mutation in the NA, 
which was first reported to the World Health Organization (WHO) by Norway in late January 2008 [11]. 
In the United States, 11% of all 2007–2008 seasonal influenza A(H1N1) viruses were resistant to 
oseltamivir [10,12], while the prevalence of oseltamivir resistance was especially high in some European 
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countries [13,14] and in Africa [15], emphasizing the critical need for NAI susceptibility surveillance of 
influenza viruses circulating globally. 
Early 2008–2009 influenza season surveillance data suggested that oseltamivir resistance among 
seasonal influenza A(H1N1) viruses would most likely be higher than in the previous 2007–2008 season 
[16]. In the present study, oseltamivir resistance was observed in 93% of seasonal influenza A(H1N1) 
virus isolates circulating globally during the 2008–2009 season, with many countries reporting up to 
100% oseltamivir resistance [17,18]. 
Assessment of NAI susceptibility is primarily performed in functional neuraminidase inhibition (NI) 
assays that allow detection of drug-resistant viruses with established mutations (e.g. H275Y in N1 
subtypes) and/or novel mutations. The most commonly used NI assays, the chemiluminescent [8,10,19,20] 
and fluorescent [21,22], both utilize small synthetic substrates [23,24] and generate IC50 values (drug 
concentration inhibiting NA activity by 50%) that are used to characterize NAI susceptibility. Both assays 
require the use of grown viruses, however, commonly used cell cultures such as the Madin-Darby canine 
kidney (MDCK) cells have been shown in some instances, to provide a growth advantage to particular 
virus variants, including those with mutations in the NA and thus may alter virus susceptibility after 
propagation [25,26]. 
Criteria defining NAI resistance were set by the Global Neuraminidase Inhibitor Susceptibility 
Network (NISN) as either IC50 >3SD from the mean (or median) or IC50 >10-fold mean (or median) for 
the influenza type/subtype and drug [27]. Resistant isolates with known and characterized drug resistance 
conferring mutations tend to have IC50 values 100–10,000 times higher than the normal range for that 
type/subtype and are clearly recognizable based on their NAI profiles. IC50 values are affected and vary by 
NI assay type, influenza virus type/subtype, and drug tested [20,21,28], requiring specific criteria for NAI 
resistance to be drawn for each factor. Nevertheless, the resulting IC50 values provide valuable information 
for detection of resistant viruses, as well as for comparison of inhibitory effects of different NAIs. The 
clinical relevance of the resistance detected using the NA inhibition assay alone has not been sufficiently 
evaluated, therefore, it is essential to monitor genetic changes in the NA and their possible effect on virus 
susceptibility to existing NAIs. 
The definitive characterization of NAI resistance combines elevated IC50 values with the presence of 
established molecular markers of resistance in the NA as determined by pyrosequencing [29,30] or 
conventional Sanger sequencing [10,21]. However, the latter criterion is hindered by insufficient 
information on markers of NAI resistance, which are not yet fully characterized. Molecular-based 
methods such as real time PCR [31,32], sequencing [10,21] or pyrosequencing [29,30] may offer rapid 
techniques for the detection of known resistance mutations, but will not identify novel mutations that may 
confer resistance, or identify subtle differences in the susceptibility of viruses to NAIs. 
For the purpose of this study, analyzed viruses included those collected during the time period (start 
day – October 1, and end day – September 30) commonly referred to as an influenza season. The study 
presents NAI surveillance data of seasonal influenza A (H1N1 and H3N2) and B viruses collected 
globally from October 01, 2008 to September 30, 2009, as well as the 2009 pandemic H1N1 viruses 
collected from April 2009 through September 30, 2009. This study defines baseline susceptibility patterns 
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of seasonal and pandemic influenza viruses, and seeks to contribute further criteria for evaluating NAI 
resistance. 
2. Results and Discussion 
2.1. Susceptibility of seasonal influenza virus isolates to neuraminidase inhibitors 
The 2008–2009 influenza season was unlike previous seasons, due to the high prevalence of 
oseltamivir resistance reported among seasonal influenza A(H1N1) viruses [17,18] and the emergence of 
the 2009 pandemic H1N1 virus in April 2009 [33]. Seasonal and pandemic influenza virus isolates  
(n = 5540) collected from different geographic regions between October 01, 2008 and September 30, 2009 
were passaged (once or twice) in MDCK cells and then routinely tested for oseltamivir and zanamivir 
sensitivity in the chemiluminescent NI assay. In addition, a subset of viruses (n = 1058) was tested for 
susceptibility to an investigational NAI, peramivir. Seasonal and pandemic reference viruses 
representative of each virus type/subtype were used as controls for the NI assay (Table 1). 
Of note, since the vast majority of 2008–2009 seasonal influenza A(H1N1) viruses exhibited elevated 
IC50s for oseltamivir when tested in the NI assay, all viruses of this subtype were tested in parallel in the 
NI assay and by pyrosequencing analysis targeted at residue H275 of the NA, to identify 
oseltamivir-resistant H275Y variants. 
Raw NI assay data were initially analyzed to determine IC50 values using curve fitting software, 
JASPR, which was recently developed at the CDC. The IC50 values generated in JASPR (Table 2) were 
highly correlated with those calculated by Robosage software (in-house, GlaxoSmithKline), which was 
previously used in NAI susceptibility studies [10,26]. Both programs can be used for curve fitting and IC50 
calculation, however, JASPR provides a faster and higher throughput method of IC50 determination, and 
has a more user-friendly format. 
To identify viruses with elevated IC50 values, box-and-whisker plot analyses of log-transformed IC50 
values [8] were performed for each virus type/subtype and respective drug (Figures 1–4). 
Log-transformation of IC50 values was necessary as they are not normally distributed parameters [8]. 
Previous surveillance studies [8,34] used box-and-whisker plot analyses to identify two kinds of outliers, 
mild (between 1.5 and 3.0 times the interquartile range (IQR) from the 25th and 75th percentile) and 
extreme (3.0 times the IQR from the 25th and 75th percentiles and at least >10-fold mean IC50). In a similar 
surveillance study [35], box-and-whisker plot analysis identified outliers as isolates with IC50 1.5 times the 
IQR from the 25th and 75th percentiles, while in another study [21] isolates with IC50 values outside the 
95% confidence limits (mean IC50 ± 2 SD) were characterized as outliers. One surveillance study [10] 
used the criterion of “mean IC50 value + 3 SD” to identify outliers; extreme outliers were isolates with 
IC50s outside this criterion and >10-fold the mean IC50 for each respective type/subtype and drug, and mild 
outliers were those with IC50s outside the cutoff criterion but <10-fold of the mean IC50 value. The same 
study [10] also performed box plot analyses of all isolates by type/subtype and drug, excluding extreme 
outliers, to determine IQR and to establish a statistical cutoff for isolates with IC50s > 3.0 times the IQR to 
the right of the third quartile (X0.75) (IC50 > X0.75 + 3 IQR). 
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In the present study, box-and-whisker plot analyses identified extreme outliers as virus isolates with 
IC50 > X0.75 + 3IQR and ≥10 -fold the mean IC50 of the drug for the virus type/subtype. Mild outliers were 
isolates with IC50 > X0.75 + 3IQR, but >2-fold and <10-fold that of the mean IC50 of the drug for the virus 
type/subtype. These criteria were elected for mild outliers, as using previous criterion of IC50 between 1.5 
and 3IQR from the 75th percentile [8,34,36] resulted in the characterization of too many isolates without 
genetic changes in the NA as outliers. Outliers with IC50s below the 25th percentile were not characterized, 
but were considered NAI-susceptible. 
In this study, the box-and-whisker plot analysis to determine outliers for oseltamivir among seasonal 
influenza A(H1N1) virus isolates tested (n = 1533) revealed two diverse clusters of oseltamivir IC50s 
(Figure 1). All viruses with IC50s in the upper cluster (n = 1431) harbored the H275Y 
oseltamivir-resistance conferring mutation in their NA, based on pyrosequencing analysis, and were 
reported as oseltamivir-resistant, while those with IC50s in the lower cluster located 3IQR below the 25th 
percentile (n = 102) exhibited wildtype sequence at residue H275 of the NA. 
The distribution of peramivir IC50 values (Figure 2) among seasonal influenza A(H1N1) viruses  
(n = 235) was similar to that of oseltamivir IC50s for this subtype (Figure 1), with a distinct separation of 
H275Y variants (n = 216) and H275 wildtype viruses (n = 19). However, the distribution of zanamivir 
IC50 values (Figure 3) among seasonal influenza A(H1N1) virus isolates tested for the drug (n = 1533) did 
not distinguish H275Y variants from viruses lacking the mutation. 
As a result of the distinct clustering of IC50s observed in box-and-whisker plots for oseltamivir and 
peramivir among seasonal influenza A(H1N1) viruses, it was necessary to perform additional similar 
analyses on oseltamivir-susceptible (H275 wildtype) viruses alone, for both drugs (Figure 4), in order to 
set a statistical cutoff and baseline for oseltamivir and peramivir susceptibility for this subtype, and to 
identify mild outliers lacking H275Y which may harbor novel mutations in the NA. In addition, the 
descriptive statistics of IC50 values for each drug were computed separately for seasonal influenza 
A(H1N1) H275Y variants and H275 wildtype viruses, given their distinctive drug resistance genotypes 
and phenotypes (Table 3). 
Following box-and-whisker plot analyses for H275 wildtype viruses (Figure 4), statistical cutoffs of 
0.58 nM and 0.28 nM for oseltamivir and peramivir, respectively, were determined based on the criterion 
IC50>X0.75 + 3IQR (Table 3). All seasonal influenza A(H1N1) H275Y variants were outliers for 
oseltamivir and peramivir based on this criterion, in addition to having IC50≥10-fold mean IC50 for the 
respective drugs. A few outliers for oseltamivir (n = 4) were identified among H275 wildtype seasonal 
influenza A(H1N1) viruses (Figure 4) including A/Shannxi-Beilin/1264/2008 (H1N1) which showed a 
mix at residue D151 of the NA (D151D/N). A similar mix (D151D/N) was also observed in the isolate 
A/Shanghai-Nanhui/1156/08 (H1N1), the only peramivir outlier among the H275 wildtype viruses. These 
outliers exhibited IC50s that were only 2- to 4-fold more than the mean IC50 for the respective drugs 
(Table 3). 
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Table 1. Reference viruses used as controls in the chemiluminescent NI Assay. 
Strain Designation Type/Subtype NA Mutations (Genotype) 
Oseltamivir 
Susceptibility 
Mean IC50a ± SDb, nM (Fold Difference c) 
Oseltamivir Zanamivir Peramivir 
A/Washington/10/2008 A (H1N1); Seasonal WTd Se 0.23±0.07 (1) 0.24±0.08 (1) 0.09±0.02 (1) 
A/Florida/21/2008 A (H1N1); Seasonal H275Y Rf 94.82±27.04 (386) 0.31±0.08 (1) 11.27±1.36 (134) 
A/Washington/01/2007 A (H3N2); Seasonal WT S 0.15±0.00 (1) 0.47±0.04 (1) 0.12±0.02 (1) 
A/Texas/12/2007 A (H3N2); Seasonal E119V R 4.19±0.33 (30) 0.51±0.05 (1) 0.14±0.02 (1) 
B/Memphis/20/1996 B; Seasonal WT S 1.61±0.21 (1) 1.94±0.21 (1) 0.31±0.06 (1) 
B/Memphis/20/1996 B; Seasonal R152K R 82.62±2.96 (58) 26.35±13.59 (22) 52.80±3.51 (176) 
A/California/07/2009 H1N1; Pandemic WT S 0.21±0.03 (1) 0.26±0.04 (1) 0.06±0.02 (1) 
A/Texas/48/2009 H1N1; Pandemic H275Y R 79.94±0.06 (348) 0.36±0.07 (1) 10.06±0.01 (164) 
a Average of 3 independent assays. b SD, Standard Deviation of IC50 values. c Fold difference in IC50 values between mutant and wildtype viruses, by drug 
and virus type/subtype (IC50 of mutant/IC50 of wildtype virus). d WT, Wildtype e S, Sensitive (Susceptible). f R, Resistant. 
Table 2. Comparison of neuraminidase inhibition IC50 data generated by JASPR and Robosage software. 
Subtype Isolates analyzed (n) 
Mean IC50 a (±SD)b, nM 
Oseltamivir Zanamivir 
JASPR Robosage rc JASPR Robosage r 
Seasonal A/H1N1 (H275 wildtype)d 8 0.22±0.05 0.26±0.07 0.970 0.47±0.34 0.56±0.47 0.999 
Seasonal A/H1N1 (H275Y variants)e 106 113.38±45.63 128.57±55.93 0.986 0.50±0.23 0.58±0.30 0.990 
Pandemic H1N1 100 0.21±0.06 0.25±0.06 0.939 0.28±0.10 0.31±0.13 0.988 
A/H3N2 125 0.24±0.13 0.27±0.16 0.994 1.30±0.93 1.48±1.08 0.994 
B 106 3.56±0.94 3.84±1.05 0.990 3.93±1.32 4.19±1.45 0.995 
a Determined in the chemiluminescent neuraminidase inhibition assay. b SD, standard deviation of IC50 values. c r, Pearson correlation coefficient. d H275 
wildtype, oseltamivir-sensitive isolates. e H275Y variants, oseltamivir-resistant virus isolates.
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Figure 1. Box-and-whisker plots showing distributions of log-transformed oseltamivir IC50 
values for seasonal influenza A(H1N1) (n = 1533), 2009 pandemic H1N1 (n = 2259), seasonal 
influenza A(H3N2) (n = 834), and seasonal influenza B (n = 914) virus isolates. The boxes 
represent the 25th to 75th percentiles, and horizontal lines within the box represent median 
values. The whiskers represent the lowest and highest value in the 25th percentile minus 
1.5IQR and 75th percentile plus 1.5IQR regions, respectively. 
 
 
The mean IC50 for oseltamivir among H275Y variants (123.32 nM) was ~500-fold greater than that of 
the H275 wildtype viruses (0.23 nM; Table 3) and the oseltamivir-sensitive control virus, 
A/Washington/10/2008 (0.23 nM; Table 1), and was 135-fold more than the mean IC50 for oseltamivir 
(0.91 nM) previously published for seasonal influenza A(H1N1) viruses collected between 2004–2007 
and also tested in the chemiluminescent NI assay [10]. The mean IC50 for peramivir among the H275Y 
variants (30.56 nM) was ~300-fold more than that of viruses lacking this mutation (0.10 nM), as well as 
that of the oseltamivir-sensitive control virus, A/Washington/10/2008 (0.09 nM). A wide variation in IC50 
values was observed among the H275Y variants (14.71-1023.68 nM), but not the H275 wildtype viruses 
(0.1-0.49 nM). The isolate, A/England/412/2008 (H1N1), with an IC50 of 14.71 nM for oseltamivir 
exhibited the presence of mixed wildtype and mutant sequences at residue H275 (H275H/Y) following 
full NA sequence analysis. This isolate also exhibited a lower IC50 (0.51 nM) for peramivir compared to 
other H275Y variants and was excluded from the descriptive statistical analyses of the respective drug 
IC50s among seasonal influenza A(H1N1) H275Y variants. The highest IC50 for oseltamivir (1023.68 nM) 
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was observed in the A/Thailand/1035/2008 (H1N1) which exhibited dominant H275Y mutation in 
addition to a mix of wildtype and mutant sequences at residue D151 (D151D/G). This isolate was also an 
outlier for zanamivir (20.61 nM) and peramivir (295.21 nM). The IC50 values for oseltamivir among 
seasonal influenza A(H1N1) viruses comprising populations of 100% H275Y variants without mutations 
at D151 in the NA ranged from 34.69 nM to 657.88 nM. 
All seasonal influenza A(H1N1) viruses tested for zanamivir (n = 1533) were sensitive to the drug, 
with the exception of some outliers (n = 6) among the H275Y variants whose IC50s were above the 
statistical cutoff of 1.05 nM and ≥10-fold mean IC50 (0.51 nM) for this group of viruses (Table 3). The 
outliers included A/Thailand/1035/2008 (H1N1) mentioned above, and A/Hawaii/20/2008 (H1N1), both 
with H275Y and D151D/G mutations in their NA. The presence of concurrent mutations at NA residues 
H275 and D151 in seasonal influenza A(H1N1) virus isolates substantially enhances resistance to 
oseltamivir and peramivir and/or zanamivir, however, the changes at D151 are typically cell-derived and 
not present in clinical specimens [26]. 
Figure 2. Box-and-whisker plots showing distribution of log-transformed peramivir IC50 
values for seasonal influenza A(H1N1) (n = 235), 2009 pandemic H1N1 (n = 550), seasonal 
influenza A(H3N2) (n = 220), and seasonal influenza B (n = 52). The boxes represent the 25th 
to 75th percentiles, and horizontal lines within the box represent median values. The whiskers 
represent the lowest and highest value in the 25th percentile minus 1.5IQR and 75th percentile 
plus 1.5IQR regions, respectively. 
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Table 3. Neuraminidase inhibitor susceptibility of seasonal influenza virus isolates (2008-2009). 
 
NAI  
Influenza Type/Subtype 
 
Isolates 
analyzed (n)* 
IC50 (nM)a 
Range Mean (±SD)b Median IQRd X0.75 e 
Statistical 
Cutoff f 
Oseltamivir A(H1N1) (H275 wildtype)g 98 0.10-.0.49 0.23±0.08 0.21 0.10 0.28 0.58 
 A(H1N1) (H275Y variants)h 1430 34.69-1023.68 123.32±65.90 105.13 -- -- -- 
         
 A/H3N2 833 0.04-1.38 0.24±0.15 0.20 0.15 0.29 0.74 
         
 B 913 0.59-7.75 3.41±0.99 3.38 1.27 4.01 7.82 
         
Zanamivir A(H1N1) (H275 wildtype)g 102 0.13-1.03 0.35±0.15 0.31 0.17 0.54 1.05 
 A(H1N1) (H275Y variants)h 1424 0.07-3.49 0.51±0.27 0.45 -- -- -- 
         
 A(H3N2) 812 0.22-4.24 1.23±0.80 0.97 0.91 1.58 4.31 
         
 B 911 0.27-8.77 3.34±1.31 3.27 1.94 4.24 10.06 
         
Peramivir A(H1N1) (H275 wildtype) 19 0.05-0.17 0.10±0.03 0.10 0.05 0.13 0.28 
 A(H1N1) (H275Y variants) 215 2.46-510.57 30.56±66.06 12.95 -- -- -- 
         
 A/H3N2 219 0.05-0.94 0.17±0.10 0.14 0.07 0.19 0.40 
         
 B 52 0.24-1.10 0.56±0.18 0.56 0.23 0.68 1.37 
a Determined in the chemiluminescent neuraminidase inhibition assay. *Outliers and mixes (comprising wildtype and variant populations) were excluded from the 
calculation of mean, SD and median of IC50 values. b SD, Standard Deviation of IC50 values. c Cutoff IC50 value for NAI-susceptible viruses, determined by Mean IC50+3SD. 
d IQR, Interquartile Range. e X0.75, 75th Percentile. f Statistical cutoff of IC50 values for NAI susceptibility, determined by X0.75 + 3IQR. Outliers with IC50 above this cutoff and 
>10 times the mean IC50 for each drug, were characterized as extreme outliers; those with known drug-resistance mutations such as H275Y were classified as resistant and 
analyzed separately. g H275 wildtype, oseltamivir-susceptible isolates. h H275Y variants, oseltamivir-resistant virus isolates. 
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All seasonal influenza A(H3N2) viruses tested for oseltamivir (n = 834) were sensitive to the drug 
(Figure 3 and Table 3), with exception of one outlier, A/Ontario/RV0442/2009, with an IC50 of 2.50 
nM, which was beyond the IC50 cutoff (0.74 nM) and ≥10 -fold mean IC50 for the drug (0.24 nM). 
A/Ontario/RV0442/2009, which was also the only outlier for peramivir (7.48 nM) among A(H3N2) 
viruses tested for peramivir (n = 220), was an outlier for zanamivir as well (221.06 nM). Full NA 
sequence analysis of A/Ontario/RV0442/2009 revealed the presence of a D151V mutation in addition 
to V50M. The D151V mutation was previously detected in the NA of A/Montana/8/2007 [10] where it 
resulted in a 150-fold decrease in zanamivir susceptibility compared to a zanamivir-sensitive virus. 
Figure 3. Box-and-whisker plots showing distributions of log-transformed zanamivir IC50 
values for seasonal influenza A(H1N1) (n = 1533), 2009 pandemic H1N1 (n = 2259), 
seasonal influenza A(H3N2) (n = 834), and seasonal influenza B (n = 914) virus isolates. 
The boxes represent the 25th to 75th percentiles, and horizontal lines within the box 
represent median values. The whiskers represent the lowest and highest value in the 25th 
percentile minus 1.5IQR and 75th percentile plus 1.5IQR regions, respectively. 
 
 
The majority of seasonal influenza A(H3N2) viruses were sensitive to zanamivir, with exception of 
some outliers (n = 3) with IC50 beyond the statistical cutoff (4.31 nM) and ≥10-fold mean IC50 for the 
drug (1.23 nM), including the above-mentioned A/Ontario/RV0442/2009, as well as 
A/Maryland/02/2009 (16.21 nM) and A/Vladivostok/53/2009 (21.31 nM) whose full NA sequences 
revealed the presence of D151G and mixed D151D/G mutations, respectively. In addition, a few mild 
zanamivir outliers (n = 19) with IC50 beyond the statistical cutoff but <10-fold mean IC50 for the drug 
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were also identified. Sequence data available for nine of these viruses showed the presence of wildtype 
and mutant sequences at residue 151 of the NA, namely, D151D/G (6 isolates), D151D/N (2 isolates) 
and D151D/A (1 isolate). Mutations at residue D151 of the NA are associated with reduced 
susceptibility to zanamivir in A(H3N2) viruses [10], however, these mutations have been shown to be 
cell culture derived in recent H3N2 viruses [37]. 
Figure 4. Box-and-whisker plots showing distributions of log-transformed IC50 values for 
oseltamivir carboxylate and peramivir among oseltamivir-sensitive (wildtype H275) 
seasonal influenza A(H1N1) virus isolates (n = 102). The boxes represent the 25th to 75th 
percentiles, and horizontal lines within the box represent median values. The whiskers 
represent the lowest and highest value in the 25th percentile minus 1.5IQR and 75th 
percentile plus 1.5IQR regions, respectively. 
 
 
All influenza B viruses tested for oseltamivir (n = 914) were sensitive to the drug with the exception 
of one outlier B/Texas/38/2008 with an IC50 of 12.70 nM; this IC50 value was only 4-fold greater than 
the mean IC50 for oseltamivir (3.41 nM) among B viruses tested (Table 3) and 8-fold that of an 
oseltamivir-sensitive control virus B/Memphis/20/96 (wildtype) (Table 1). This isolate, 
B/Texas/38/2008, was also an outlier for zanamivir (10.35 nM); its full NA sequence analysis revealed 
the presence of D197E mutation (corresponding to D198E in N2 numbering). Previously, an influenza 
B virus with D197E mutation which demonstrated a significant reduction in sensitivity to oseltamivir 
and zanamivir was detected in a patient with no history of treatment or contact with neuraminidase 
inhibitors [38]. 
The influenza B viruses tested for peramivir susceptibility (n = 52) were all sensitive to the drug, 
while those tested for zanamivir (n = 914) were susceptible to the drug, with the exception of the 
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above-mentioned isolate, B/Texas/38/2008, with the D197E mutation and two other isolates B/New 
Jersey/02/2009 and B/Okinawa/10/2009 which also exhibited reduced susceptibility to the drug. 
However, full NA sequence analysis of both B/New Jersey/02/2009 and B/Okinawa/10/2009 did not 
reveal any changes that may explain the reduced zanamivir susceptibility. 
2.2. Susceptibility of 2009 pandemic H1N1 viruses to neuraminidase inhibitors 
A total of 16 outliers (Figure 1) were identified among the pandemic influenza H1N1 viruses tested 
for oseltamivir susceptibility (n = 2259), 15 of which were H275Y variants and were characterized as 
oseltamivir-resistant, while one virus, A/Chile/1579/2009, lacked the H275Y mutation but harbored 
the mutation I223K (I222K in N2 numbering) in its NA. This isolate, A/Chile/1579/2009, exhibited an 
IC50 for oseltamivir (2.84 nM), which was 12-fold greater than the mean IC50 for the drug among H275 
wildtype viruses (0.25 nM; Table 4) and 14-fold greater than the IC50 for the oseltamivir-sensitive 
control virus A/California/07/2009 (0.21 nM; Table 1). Of note, full NA sequence analysis of the 
pandemic isolate, A/Utah/34/2009, with the lowest IC50 for oseltamivir among H275Y variants 
(6.24 nM), revealed the presence of mixed wildtype and mutant sequences at residue H275 
(H275H/Y). This isolate was excluded from descriptive statistical analysis of IC50s for pandemic 
H1N1 H275Y variants (Table 4). 
All pandemic H1N1 viruses tested for peramivir susceptibility (n = 550) were sensitive to the drug, 
with the exception of 12 outliers, all of which were H275Y variants. 
In contrast to seasonal influenza A(H1N1) viruses, box-and-whisker plot analyses performed on all 
pandemic influenza H1N1 viruses tested for oseltamivir and peramivir (Figure 1) versus that 
performed only on pandemic H275 wildtype viruses (figure not shown) yielded the same statistical 
cutoff, since only a few H275Y variants (0.7%) were detected among the pandemic influenza H1N1 
viruses as opposed to 93% among seasonal influenza A(H1N1) viruses. Similar to the seasonal 
influenza A(H1N1) viruses, descriptive statistical analyses of oseltamivir and peramivir IC50s for 
pandemic H1N1 H275Y variants were performed separately from those of H275 wildtype viruses 
(Table 4), given their distinct genotypes and phenotypes. 
All pandemic H1N1 virus isolates tested for zanamivir (n = 2259) were sensitive to the drug, except 
for a few outliers (n = 11) whose IC50s were above the statistical cutoff of 0.69 nM, however, their 
IC50s were <10-fold that of the mean IC50 for the drug (0.31 nM), and only one outlier, 
A/Chile/1579/2009 with an IC50 of 0.89 nM showed a change in the NA sequence (I223K). This IC50 
(0.89 nM) was only 3-fold higher than the mean IC50 for zanamivir among this subtype (0.31 nM). 
There were no apparent differences between the mean IC50 of zanamivir for H275Y variants (0.38 nM) 
and H275 wildtype viruses (0.31 nM) (Table 4). 
2.3. Challenges of defining neuraminidase inhibitor resistance for surveillance 
There is no precise definition of resistance to NAIs in the NI assay because there is currently no 
established and clinically relevant cutoff IC50 value which would separate sensitive viruses from 
resistant ones. Elevated IC50s must be combined with detection of known molecular markers of 
resistance by conventional sequencing [10,21] or pyrosequencing [29,30] to define NAI resistance. 
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In this study, seasonal or 2009 pandemic H1N1 viruses initially identified as outliers for oseltamivir 
based on elevated IC50 values, were only characterized as oseltamivir-resistant following 
pyrosequencing analysis to confirm the presence of the H275Y mutation. Outliers among influenza 
A(H3N2) viruses were shown to harbor mutations at D151 that were earlier associated with reduced 
susceptibility to zanamivir [10], however virus variants with mutations at residue D151 in N1 and N2 
NAs have been shown to be cell culture selected [26,37], therefore, D151 variants may aptly be 
reported as NAI-sensitive. It is imperative to confirm the presence of identified molecular markers of 
resistance in the NA of matching primary clinical specimens by conventional sequencing or 
pyrosequencing. 
Various technical difficulties are associated with determining NAI resistance in influenza viruses. 
Cell culture-based assays cannot be used for antiviral susceptibility surveillance studies because 
interpretation of NAI susceptibility in such assays is unreliable [27]. Functional NI assays 
(chemiluminescent or fluorescent) therefore remain the primary means of monitoring susceptibility of 
influenza viruses to NAIs. Typically, the fluorescent NI assay generates higher IC50 values than the 
chemiluminescent assay [39] and offers a better discrimination between the IC50 values of the mutant 
and wild type viruses; however, it requires higher virus titers than the chemiluminescent assay. The NI 
assay’s requirement for cell culture propagated viruses offers challenges in defining NAI resistance as 
studies have shown that even in the absence of drug pressure, propagation of virus outside of the 
natural host (i.e., MDCK cells) can lead in some cases, to selection of NA variants with altered 
susceptibility to NAIs [25,26]. For surveillance purposes, it is easy to define resistance in the NI assay, 
for extreme outliers. However, additional studies are required to define meaningful cutoff values for 
NAI susceptibility. The definition of resistance could be harmonized through the sharing of resistant 
reference virus strains and utilization of similar methods for the assessment of IC50 values by various 
laboratories, especially for viruses with resistance demonstrated in clinical studies. 
Setting criteria for NAI resistance based on IC50 values requires the identification of outliers, which 
in this study was done by box-and-whisker plot analyses [8]. Box-and-whisker plots typically display 
differences between populations without making assumptions about the underlying statistical 
distribution. In this study, initial box-and-whisker plot analysis on seasonal influenza A/H1N1 viruses 
was performed without assuming that these viruses consisted of different populations (H275 wildtype 
and H275Y mutants). After visualizing the distributions of IC50s on these plots (Figure 1), it was 
necessary to perform additional box-and-whisker plot analysis on H275 wildtype viruses to determine 
whether there were outliers among this population that may have had mutations in the NA other than 
H275Y. There is no set proportion of obvious outliers allowed for proper box-and-whisker plot 
analysis as a dataset might have no outliers, one outlier, or several outliers. 
Characterization of NAI resistance in the NI assay is further complicated by the differences in 
ranges of IC50 values between influenza types/subtypes for oseltamivir, zanamivir and other NAIs such 
as peramivir, which makes it impossible to compare type/subtype and drug specific data. The IC50 
values may also be affected by assay conditions and may differ for the same virus between assays. In 
this study, for example, the mean IC50 for oseltamivir among influenza B viruses tested (3.41 nM) was 
~14-fold higher than those of seasonal influenza A(H1N1) H275 wildtype, A(H3N2) and pandemic 
H1N1 H275 wildtype viruses whose mean IC50s for the drug were 0.23, 0.24 and 0.25 nM, respectively 
(Tables 3 and 4). In addition, the influenza B viruses exhibited mean IC50s for zanamivir (3.34 nM) 
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and peramivir (0.56 nM) which were 2- to 10-fold and 3- to 7-fold higher, respectively, than those of 
the seasonal and pandemic influenza A viruses tested. Lower susceptibility of influenza B viruses to 
NAIs compared to influenza A viruses was demonstrated in several studies [8,10,21]. Clinical studies 
[40,41] have shown oseltamivir to be somewhat less effective against influenza B compared to 
influenza A virus infections in young children, probably due to the reduced sensitivity of type B 
viruses to oseltamivir. 
The IC50s for different NAIs also differ within each virus type/subtype [20,21,33,42]. It was 
reported that IC50s for influenza B viruses were higher for oseltamivir than for zanamivir [42], but in 
our study the influenza B viruses exhibited IC50s that were comparable for both drugs, 3.41 nM and 
3.34 nM, respectively (Table 3), and were in agreement with mean IC50s published for B viruses 
circulating between 2004–2007 using a similar chemiluminescent NI assay [10]. Among the seasonal 
influenza A(H1N1) viruses, the mean IC50 for zanamivir was ~3-fold higher than that of oseltamivir, 
similar to previous studies where IC50s for zanamivir were slightly higher than for oseltamivir: by  
1.2-fold in [10] and 1.5-fold in [21]. The influenza A(H3N2) viruses were less sensitive to zanamivir 
than oseltamivir, exhibiting a mean IC50 for zanamivir 7-fold greater than that of oseltamivir, in 
agreement with a 4-fold difference [21] and a 6-fold difference published for influenza A(H3N2) 
viruses circulating between 2004-2007 [10]. The pandemic H1N1 wildtype viruses, on the other hand, 
exhibited mean IC50s for oseltamivir and zanamivir that were quite similar, 0.24 nM and 0.30 nM, 
respectively. All virus type/subtypes tested for peramivir exhibited IC50s for the drug that were  
2-8 times lower than those of oseltamivir and zanamivir, with exception of seasonal influenza 
A(H3N2) viruses whose IC50s for oseltamivir (0.24 nM) and peramivir (0.17 nM) were similar. 
Wide variations in IC50s for oseltamivir were observed among seasonal influenza A(H1N1) and 
pandemic H1N1 H275Y variants, with the seasonal isolate A/England/412/2008 (14.71 nM) and 
pandemic isolate A/Utah/34/2009 (6.24 nM) exhibiting the lowest IC50s for oseltamivir which were 
~10-fold lower than the mean IC50s for the drug among the respective H275Y variants. Both isolates 
showed mixes of wildtype and mutant nucleotide sequences at residue 275 of the NA (H275H/Y) and 
were excluded from descriptive statistical analyses of seasonal and pandemic H275Y variants, 
respectively. The presence of wildtype and mutant virus populations in a sample may affect the 
accuracy of setting definitive criteria for the detection of NAI resistance [26], although such mixes can 
evolve into fully resistant dominant variant populations with further passage of virus isolates. By 
contrast, the seasonal influenza A(H1N1) isolate with the highest IC50 for oseltamivir, 
A/Thailand/1035/2008, had a dominant H275Y mutation in addition to a mix of wildtype and mutant 
sequences at residue D151 (D151D/G). The IC50 for this isolate (1023.68 nM) was ~10-fold higher 
than the mean IC50 for the drug among seasonal influenza A(H1N1) H275Y variants, stressing further 
the complexity of defining a precise criterion for NAI resistance based on NI assay IC50 values. Hence, 
when defining criteria for resistance to an NAI such as oseltamivir, only IC50 values of viruses lacking 
the cell selected mutations such as those at residue D151 should be evaluated. 
Viruses 2010, 2                            
 
 
2283 
Table 4. Neuraminidase inhibitor susceptibility of 2009 pandemic H1N1 virus isolates (2008-2009 season). 
NAI 
Pandemic 
H1N1 virus 
isolates 
Isolates 
analyzed 
(n)* 
IC50 (nM)a 
Range Mean (±SD)b Median IQRc X0.75 d 
Statistical 
Cutoff e 
Oseltamivir H275 wildtypef 2243 0.05-1.78 0.25±0.11 0.24 0.08 0.28 0.52 
 H275Y variantsg 14 54.21-155.00 87.57±25.53 80.30 -- -- -- 
         
Zanamivir H275 wildtypef 2233 0.08-1.03 0.31±0.08 0.30 0.11 0.36 0.69 
 H275Y variantsg 14 0.27-0.53 0.38±0.08 0.36    
         
Peramivir H275 wildtype 538 0.03-0.35 0.08±0.04 0.07 0.04 0.10 0.22 
 H275Y variants 11 8.1-12.91 10.40±1.37 10.29 -- -- -- 
a Determined in the chemiluminescent neuraminidase inhibition assay. *Outliers and mixes (comprising wildtype and variant populations) were 
excluded from the calculation of mean, SD and median of IC50 values. b SD, standard deviation of IC50 values. c IQR, interquartile range. d X0.75, 
75th Percentile. e Statistical cutoff of IC50 values for NAI susceptibility, determined by X0.75 + 3IQR. Outliers with IC50 above this cutoff and  
>10 times the mean IC50 for each drug, were characterized as extreme outliers; those with known drug-resistance mutations such as H275Y were 
classified as resistant and analyzed separately. f H275 wildtype, oseltamivir-susceptible pandemic virus isolates. g H275Y variants, oseltamivir-
resistant pandemic virus isolates. 
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3. Experimental Section 
3.1. Viruses and cells 
Seasonal and pandemic influenza viruses collected between October 01, 2008 and September 30, 
2009 from various geographic regions of the world were submitted to the WHO Collaborating Center 
for Surveillance, Epidemiology and Control of Influenza at the Centers for Disease Control and 
Prevention (CDC) in Atlanta, GA, U.S., and propagated in Madin-Darby canine kidney (MDCK) cells 
(ATCC, Manassas, VA) that were maintained in Dulbecco’s modified eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FCS), 50 units/ml penicillin and 50 µg/ml streptomycin 
(Invitrogen, Carlsbad, CA). Oseltamivir-sensitive and -resistant reference viruses representing each 
antigenic type and subtype were also propagated in MDCK cells. 
3.2. NA inhibitors 
Oseltamivir carboxylate, the active compound of the ethyl ester prodrug oseltamivir phosphate was 
supplied by Hoffmann-La Roche (Basel, Switzerland), zanamivir by GlaxoSmithKline (Uxbridge, 
U.K.) and peramivir by BioCryst Pharmaceuticals (Birmingham, AL). 
3.3. NA inhibition assays 
Susceptibilities of viruses to NAIs were assessed in the chemiluminescent NI assay using the 
NA-Star™ Kit (Applied Biosystems, Foster City, CA) as previously described [10]. 
3.4. Statistical analysis 
Fifty percent inhibitory concentration (IC50) values were calculated using JASPR curve fitting 
software, an in-house program developed at CDC. JASPR is freely available from the CDC and can be 
obtained through Dr. Larisa Gubareva (lgubareva@cdc.gov). Comparative curve fitting on a subset of 
viruses was performed by Robosage version 7.31 software (GlaxoSmithKline, Research Triangle Park, 
NC), an add-in for MS Excel (Microsoft Corp., Redmond, WA). Curve fitting in JASPR was done 
using the equation: V = Vmax * (1 - ([I] / (Ki + [I]))), where Vmax is the maximum rate of 
metabolism, [I] is the inhibitor concentration, V is the response being inhibited, and Ki is the IC50 for 
the inhibition curve. Curve fitting in Robosage was done using the equation: y = Vmax*(1-(x/(K+x))), 
where Vmax is the maximum rate of metabolism, x is the inhibitor concentration, y is the response 
being inhibited, and K is the IC50 for the inhibition curve (i.e., y = 50%Vmax when x = K). 
Box-and-whisker plot analyses [8] of log-transformed IC50 values were performed for each drug and 
virus type/subtype using SAS 9.2 software (SAS Institute, NC, U.S.) to determine quartiles and 
interquartile ranges (IQR) necessary for establishing statistical cutoffs for identification of potentially 
resistant viruses (outliers). Log-transformation of IC50 values was necessary as they are not a normally 
distributed parameter [8]. The statistical cutoff was set at three times the IQR to the right of the third 
quartile (X0.75) [10]. All viruses with IC50s outside this cutoff (IC50 > X0.75 + 3 IQR) and with IC50  
>2-fold but <10-fold the mean IC50 for the respective drug for each type/subtype were characterized as 
mild outliers, while those with IC50 > X0.75 + 3 IQR and ≥10 -fold the mean IC50 for drug for each 
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respective type/subtype were considered extreme outliers. Outliers were subjected to genetic analysis 
by pyrosequencing and/or conventional sequencing to detect known or novel markers of NAI 
resistance. Those harboring previously characterized NA mutations associated with NAI resistance 
were considered drug-resistant; their descriptive statistics were determined separately. 
Descriptive statistics to compute the mean, median and standard deviation (SD), and a one-way 
analysis of variance were performed on original IC50 data (not log transformed), using SAS 9.2 
software (SAS Institute, NC, U.S.) for each drug and virus type/subtype, excluding outliers, with 
statistical significance set at α = 0.05. Virus isolates comprising mixes of both wildtype and variant 
populations were also excluded from the descriptive statistical analyses. 
3.5. Pyrosequencing 
Viral RNA extraction, reverse transcription PCR (RT-PCR) and pyrosequencing on the PyroMark 
ID platform (Biotage AB, Uppsala, Sweden) to detect molecular markers of NAI resistance in the NA 
were performed as previously described [29,30]. Generated sequences were aligned and analyzed 
using Identifire software (Biotage AB, Uppsala, Sweden). 
3.6. Sequencing by dideoxy chain termination method 
Full sequencing of the NA gene to detect markers of NAI resistance was performed as previously 
described [10]. Briefly, viral RNAs were extracted from isolates using the MagNA Pure LC or 
Compact platforms (Roche, Indianapolis, IN). Reverse transcription polymerase chain reaction  
(RT-PCR) was performed using the SuperScript III One-Step HiFi RT-PCR Kit (Invitrogen). 
Amplified PCR products were purified using ExoSAP-IT® reagent (USB, Cleveland, OH). Sequence 
template synthesized with ABI Prism® BigDye™ Terminator Kit (Applied Biosystems, Foster City, 
CA) and purified using ABI Prism® BigDye™ XTerminator Kit (Applied Biosystems, Foster City, 
CA). Sequences generated in an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems, Foster 
City, CA) and analyzed using Lasergene® DNAStar software version 7.0 (DNAStar, Madison, WI, 
U.S.). 
4. Conclusions 
The IC50 values resulting from the NI assay provide valuable information for detection of resistant 
viruses, but they should not be used to draw a direct correlation with the drug concentrations needed to 
inhibit virus replication in the infected human host, as clinical data to support such inferences are 
inadequate. Assessment of NAI susceptibility of virus in the NI assay, supported by NA sequencing in 
the virus isolate and its matching clinical specimen, provides a reliable and reasonably comprehensive 
approach to the identification of NAI-resistant isolates for surveillance purposes. However, there is a 
pressing need to establish a clinically relevant IC50 cutoff value which could be used to differentiate 
statistical outliers from truly resistant viruses. Global surveillance for NAI resistance should be 
sustained to reflect the impact of seasonal and pandemic of influenza, and also to reflect the increasing 
use of different NAIs and development of novel NAIs. 
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